

NEXT SCIENCE®

ASX Announcement

Next Science granted its first acne-related patent

Sydney, Australia, Friday, 13 December 2019: Next Science Limited (ASX:NXS) (**Next Science or Company**) a pioneer biotechnology company, with multiple applications for commercialisation of its proprietary Xbio™ technology platform in the treatment of biofilm based infections (one of the leading causes of anti-microbial resistance), announces that it has today been granted its first acne-related patent.

The US Patent office has granted Next Science Patent No. 10,477,860 for “High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents” providing patent coverage for the application of Next Science’s unique Xbio™ technology in its Acne Gel and Acne creams.

Chronic acne is a biofilm based infection. In applying Next Science’s unique biofilm disrupting Xbio™ technology to the treatment of acne, Next Science has been able to create formulae that break up the biofilm and restore the natural biome of the skin. This new patent provides Next Science with a unique platform for the purpose of commercialisation and licensing in the field of acne treatment, in addition to the other technologies in its product portfolio.

Patent No. 10,477,860 expires on 10 May 2038.

Next Science’s wholly owned subsidiary, Next Science IP Holdings Pty Ltd, is now the owner of 22 patents granted by patent authorities in the United States, Australia, Europe, Japan and Canada.

This announcement has been authorised to be given to ASX by Next Science’s Chairman.

- - - END - - -

For further information, please contact:

Judith Mitchell, Managing Director
Phone: +61 2 8607 5124
Email: investorqueries@nextscience.com

Michael Brown
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.